The narrative around African digital health funding oscillates between two extremes: breathless excitement about record-breaking rounds and apocalyptic warnings about funding winters. Both of them miss the point. What actually matters isn’t simply how much money flows into the sector, but where the money goes, what it achieves, and whether it builds sustainable health systems or just funds expensive experiments or like we like to call it, ‘Proof of Concept’.
Understanding the difference between “money raised” and “impact delivered” has never been more critical.
A startup can announce a $10 million Series A and still struggle to achieve meaningful health outcomes or financial sustainability.
Conversely, well-capitalised ventures can burn through resources building solutions that never integrate with existing health systems or achieve clinician adoption.
The funding landscape of 2025 reflects maturation: investors are asking harder questions, founders are expected to demonstrate traction beyond just app downloads, and the gap between hype and reality is closing fast.
This article provides a comprehensive overview of Africa’s digital health funding landscape in 2025.
It examines where capital actually flowed, identifies what investors are now avoiding, and projects what 2026 will likely bring for founders and investors who are navigating this evolving ecosystem.
Snapshot Of Digital Health Funding In 2025
The overall funding climate for African digital health in 2025 reflected broader macroeconomic pressures while demonstrating sector-specific resilience.
According to Partech Africa’s 2025 annual VC report, healthtech startups raised $215 million in equity funding in 2025 (a 232% increase year-over-year), marking the first time since 2021-2022 that the sector exceeded $200 million in annual equity funding.
When combined with debt financing, total healthtech funding (equity plus debt) reached $224 million.
This significant growth must be contextualised. Healthtech funding had dropped sharply in 2024 to just $65 million (down 70% from 2023’s $212 million), making 2025’s recovery particularly notable.
The 2025 rebound occurred in a normalised market environment rather than during an expansionary peak, suggesting renewed investor conviction in scalable healthtech business models.
Key Investor Types Have Evolved In Their Approach And Priorities:
Venture capital firms became more selective, with average check sizes increasing but deal volume decreasing.
Leading Africa-focused VCs shifted toward later-stage investments in proven business models. The Partech report shows that at the venture stage (Series A and B), only seven investors closed four or more deals in 2025: Beltone Venture Capital, British International Investment, International Finance Corporation, Partech Africa, Proparco, Verod-Kepple Africa Ventures, and Y Combinator.
Development Finance Institutions (DFIs) like the International Finance Corporation, British International Investment, and the African Development Bank maintained consistent deployment in digital health.
British International Investment has been a particularly active investor in African healthtech, with investments in companies like mPharma demonstrating its commitment to ventures that deliver both development impact metrics and financial returns.
Impact funds continued deploying capital with explicit health outcome expectations, often accepting longer timelines to profitability than traditional VCs. These funds typically target ventures addressing underserved populations and support infrastructure plays that pure financial VCs might consider risky or too slow-burning.
Corporate investors and strategic players emerged as significant forces. Pharmaceutical companies, insurance providers, and telecommunications operators increasingly made strategic investments or acquisitions in digital health platforms, seeking to expand their service offerings and reach underserved markets.
Where The Money Went
Healthtech funding in 2025 was distributed across several key subsectors. While Partech’s data doesn’t break down healthtech into detailed subcategories, market observation and company-level analysis reveal several trends:
Telemedicine and virtual care platforms attracted capital, though investor interest shifted from pure-play telemedicine to hybrid models combining virtual consultations with physical touchpoints.
Platforms demonstrating patient retention, repeat consultation rates, and integration with payer systems were favoured over those with simple download or registration numbers.
Health insurance and fintech-health hybrids attracted significant interest. The convergence of health insurance, embedded finance, and care delivery created compelling value propositions.
These hybrid models address Africa’s fundamental healthcare financing challenge: out-of-pocket payments account for more than 70% of health spending in Nigeria, well exceeding the WHO’s recommended 30% threshold.
Digital platforms that can expand coverage while managing costs attract both impact-oriented and return-seeking capital.
Supply chain, pharmaceutical, and diagnostics ventures received substantial attention.
Companies like mPharma, which operates across seven African countries, continued to attract investment.
mPharma raised $35 million in a 2022 Series D round and has received subsequent backing from Growth Investment Partners (a British International Investment-backed platform) in 2025 to support expansion into Francophone West Africa, including Togo and Benin.
Data, AI, and health infrastructure players captured growing interest. Investors increasingly recognised that interoperability platforms, health information exchanges, and data infrastructure might offer more defensible business models than point solutions.
However, these ventures face longer sales cycles and complex stakeholder management.
What Investors Are Now Avoiding
The 2025 funding landscape revealed clear patterns in what investors systematically declined: Over-engineered solutions without demonstrated adoption topped the avoidance list.
The market correction from peak funding years represents healthy maturation. Investors now routinely request user retention cohorts, net promoter scores, and evidence of organic growth alongside revenue metrics.
Pure B2C models without payer alignment faced significant scepticism. Out-of-pocket healthcare spending dominates African markets, but investors learned that extracting sustainable margins from direct consumer payments proves exceptionally difficult.
Platforms that successfully raised capital either demonstrated exceptionally strong unit economics or had clear pathways to institutional payer relationships, such as employer health plans, insurance partnerships, or government contracts.
Startups with a weak regulatory strategy increasingly found it difficult to secure investments. The implementation of Kenya’s Digital Health Act and the increasing enforcement of data protection across Africa shifted regulatory compliance from “nice to have” to “must have.”
Investors also largely avoided ventures requiring behavioural change without engagement loops, platforms with a single-country focus and unclear regional expansion paths, and teams without healthcare operational experience.
Funding Gaps That Still Exist
Despite increased capital, significant funding gaps persist. Partech’s analysis shows that, at the seed-plus stage across all sectors, investor participation contracted, with funding decreasing by 4% as investors without a local presence exited the market. This pattern affected healthtech particularly acutely.
Non-English speaking markets remain systematically underfunded. Francophone Africa captured 68% of equity funding outside the “Big Four” markets (Kenya, Nigeria, South Africa, Egypt) in 2025, showing improvement.
However, language barriers, differing regulatory frameworks, and fewer established investor relationships continue to contribute to this disparity.
Infrastructure and interoperability startups face the “too important to ignore, too complex to fund” paradox.
Building health information exchanges or shared infrastructure requires significant capital and long sales cycles, yet these ventures might offer the most defensible business models in the long term.
Implementation and integration businesses represent perhaps the most significant funding gap.
These ventures specialise in deploying, customising, training users, and maintaining existing digital health solutions.
The operational backbone that determines whether platforms actually get used, yet they’re almost entirely ignored by venture capital. We barely know they exist.
What 2026 Will Likely Bring
Several trends appear poised to shape Africa’s digital health funding landscape in 2026:
Increased demand for revenue clarity and unit economics will intensify. The era of funding based primarily on user growth metrics has definitively ended.
Investors will expect clear answers to: What does customer acquisition cost? How long until a customer becomes profitable? What are retention rates beyond the first month?
Growth in public-private blended finance appears increasingly likely. WHO and the European Union announced a collaboration to support the digital transformation of health systems in sub-Saharan Africa, with an €8 million grant spanning 2025-2028, signalling the acceleration of this trend.
Regional consolidation and acquisitions will likely increase. As funding becomes more selective, smaller players struggling to achieve scale may seek exits through acquisition by better-capitalised platforms. mPharma’s 2022 acquisition of the Nigerian pharmacy chain HealthPlus prefigured this trend.
Stronger due diligence on governance and compliance will become standard. High-profile governance challenges made investors more cautious, leading to more rigorous examination of corporate governance structures, regulatory compliance, and founder backgrounds.
Advice For Founders Going Into 2026
Founders seeking funding in 2026 should understand that capital remains available for compelling opportunities, but standards have risen significantly.
How To Position Your Startup For Funding:
First, demonstrate genuine traction with quantified impact metrics. Investors increasingly expect outcome data, not just output metrics. Show health improvements attributable to your platform with validated partnerships.
Second, articulate your regulatory strategy explicitly. Which licenses do you need? What’s your data protection compliance approach? These should not be afterthoughts; they’re fundamental to operational viability.
Third, show how you’ll reach institutional revenue streams. Even if currently B2C, you have to explain the path toward B2B2C models, insurance partnerships, employer plans, or government contracts.
Metrics that will matter most include clinical outcomes data, provider or clinician satisfaction scores, payer interest indicators, regulatory compliance status, user retention cohorts, and unit economics by customer segment.
The balance has shifted decisively toward actual operational proof. Persuasive narratives about markets and visions still matter, but investors now expect stories that are backed by evidence.
Founders who can seamlessly move between inspiring vision and detailed operational metrics will be most successful.
Conclusion
Disciplined capital will shape the next generation of winners in African digital health.
The $215 million in healthtech equity funding raised in 2025 (up 232% from 2024) demonstrates that capital remains available, but it flows to ventures demonstrating operational excellence, robust regulatory framework, clear paths to sustainability, and genuine health impact, plus some levels of financial returns.
This actually represents progress and not regression. The sector needed correction from the peak-hype years.
Investors are now asking harder questions, demanding more proof, and setting higher bars for follow-on funding, which creates stronger and healthier selection pressure.
For founders, the message is clear: focus relentlessly on building businesses that actually work; that achieve adoption, deliver outcomes, generate sustainable revenue, and integrate with health systems. You must do this convincingly, and capital will remain available.
The African digital health funding landscape is not experiencing a winter; it is experiencing real-time maturation.
Mature markets generally require mature strategies. And founders who adapt to this reality will find abundant opportunities to build consequential companies that genuinely transform healthcare access and quality across the continent.
